Antipsychotic Drugs Flashcards
Arises in the ventral tegmental area (VTA)
Projects to the frontal cortex (cortical limb)
Too little DA activity (negative and cognitive symptoms)
Do not want to block DA receptors here
Projects to the nucleus accumbens (limbic limb)
Too much dopaminergic activity (positive symptoms)
Want to block DA receptors here
Mesocorticolimbic projection is involved in schizophrenia
Mesocorticolimbic projection
Blockade of D2 receptors in the striatum produces parkinsonian-like effects (extrapyramidal symptoms)
Do not want to block DA receptors here
Nigrostriatal projection
Arcuate nucleus of the hypothalamus pituitary
Endocrinological side effects due to D2 block in this location
DA suppresses prolactin, blocking D2 increases prolactin
Tuberoinfundibular system
Motor nucleus of the vagus areas around ventricles
Deals with eating behavior, blockade is associated with weight gain
Medullary-periventricular neurons
blockage results in antiemetic properties
dopamine receptors in chemotrigger zone
Typical phenothiazine antipsychotic
First agent to specifically address psychosis as opposed to simple sedation
Potentiates anesthesia
No longer often used but may be used in acute treatment of psychotic episode
Sedation, alpha 1 block (bad in the elderly)
Skin reactions, photosensitivity, cardiotoxicity, anticholinergics
Increased risk of tardive dyskinesia
chlorpromazine
Typical butyrophenone antipsychotic Major drug in schizophrenia treatment Lower sedation and less alpha block than phenothiazines Parenteral form available Severe extrapyramidal symptoms
haloperidol
First atypical antipsychotic
No extrapyramidal symptoms due to DPI selectively in mesolimbic pathway
High potency at 5HT2, better against negative symptoms than typicals
No D2 super-sensitivity
Agranulocytosis and diabetes risk, weight gain
Anticholinergic effects can cause confusion, dry mouth, orthostatic hypotension, urinary
clozapine
Atypical antipsychotic
Low risk of extrapyramidal symptoms with low doses
No evidence of agranulocytosis risk
risperidone
Atypical antipsychotic
No evidence of agranulocytosis risk
Associated with weight gain, risk of diabetes, and hyoptension
Smaller increase in serum prolactin that with haloperidol
Anticholinergic effects can cause confusion, dry mouth, urinary retention, constipation, blurred vision
olanzepine
Atypical antipsychotic
QT prolongation
ziprasidone
Atypical antipsychotic
Partial agonist at D2
Modest affinity at 5HT2 receptors (antagonist)
Partial agonist at 5HT1A receptors
No apparent risk of diabetes, lesser effect on prolactin levels
Used when depressive symptoms are present
aripiprazole
early neurological side effect of antipsychotics
Appears in 1-5 days
Anticholinergics are diagnostic and curative
Readily treatable but alarming to patient
acute dystonia (spastic retrocollis or torticollis)
early neurological side effect of antipsychotics Occurs in 5-60 days Reduce drug or change treatment Anticholinergic or propranolol may help Occurs early, tends to persist
akasthisia (motor restlessness)
early neurological side effect of antipsychotics
Occurs in 5-30 days of treatment
Bradykinesia, rigidity, mask facies, shuffling gait
Caused by antagonism of DA in striatum
Can treat with anticholinergics
parkinsonism (EPS)